Recent Updates
Recently added Catalysts
NKTR Positive Sentiment Score: 75/100

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Monday, February 9, 2026 2 min read
Key Takeaway: Nektar Therapeutics will host a conference call on February 10, 2026, to discuss topline results from the 36-week maintenance period of its Phase 2b REZOLVE-AD study. The study evaluates rezpegaldesleukin for moderate-to-severe atopic dermatitis. Results will be shared via a press release and during the webcast, which will also be available for replay.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar is set to present topline results from a significant clinical trial.
  • The investigational drug rezpegaldesleukin shows promise for treating atopic dermatitis.
  • The company is actively engaging with investors through a live webcast.

Full Press Release Details

SAN FRANCISCO,Feb. 9, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.

Conference Call

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at thisLINK.
The event, the press release and the slides will also be available on the events section of the Nektar website athttps://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visitwww.nektar.comand follow us onLinkedIn.

Contacts:

For Investors:

Vivian Wu628-895-0661[email protected]
Corey Davis, Ph.D.LifeSci Advisors, LLC[email protected]212-915-2577
Ahu Demir, Ph.D.LifeSci Advisors, LLC[email protected]212-915-3820

For Media:

Jonathan PappasLifeSci Communications857-205-4403[email protected]
SOURCE Nektar Therapeutics

Frequently Asked Questions

What is the REZOLVE-AD study about?

The REZOLVE-AD study evaluates rezpegaldesleukin for treating moderate-to-severe atopic dermatitis.

When will the conference call take place?

The conference call is scheduled for February 10, 2026, at 8:00 am ET.

How can I access the conference call?

Participants can access the live webcast through Nektar's website.

What will be discussed during the call?

Topline results from the 36-week maintenance period of the REZOLVE-AD trial will be discussed.

Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics rezpegaldesleukin atopic dermatitis Phase 2b study clinical trial
Last updated: Feb 9, 2026